Related to $3.25B Tysabri Deal a Win-Win for Biogen Idec, Elan

• Eisai’s Epilepsy Therapy Meets Goals in First of Three Phase III Trials
  
• TPP and Edinburgh University Team Up to Develop Preclinical IP for Multiple Diseases
  
• Canada Grants GW Pharm’s Sativex Full Approval for MS Spasticity
  
• Pfizer Makes Another Move into Orphan Drug Development with Purchase of FoldRx
  
• Ipsen Acquires Santhera’s Parkinson Drug for €13M Up Front
  
• iPierian Ups Series B Financing Total to $28M
  
• Shire Pays Acceleron $45M Up Front for Neuromuscular Disease Candidates
  
• Russian Authorities Become First to Sanction Novartis’ Oral MS Therapy
  
• Addex to Pocket CHF20M to Move PD Therapy into Phase II
  
• NIH Ponies Up $40M to Map the Brain’s Connections
  
• GSK and Genmab Focus on Subcutaneous Ofatumumab for Autoimmune Diseases
  
• Belgian Tech-Transfer Organization Gets Additional €16M from K.U. Leuven and EIF
  
• Proximagen Gains Compound Hits for CXCR4 Target from Ligand Pharmaceuticals
  
• Aquapharm and Dundee University Team Up to Discover Marine-Derived Drugs against AD
  
• Novartis Gets FDA OK for MS Therapy and Makes Headway against Cushing Disease
  
• DSP Nabs U.S. and Canadian Marketing Option to SanBio’s Phase I Cell Therapy
  
• Banyan Gets $26.3M to Develop Point-of-Care Diagnostic for Brain Injury
  
• Lundbeck Pays Genmab €7.5 Up Front in Deal Focused on CNS Diseases
  
• Sanofi-Aventis’ Teriflunomide Comes Up Trumps in Two-Year Phase III MS Trial
  
• Index Pledges €10M to New Company’s Development of Peptide Candidates for CNS Diseases